Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children

Shinefield, Henry R.; Black, Steven; Staehle, Brenda; Matthews, Holly; Adelman, T; Ensor, Kathleen; Li, Shu; Chan, Ivan S. F.; Heyse, Joseph F.; Waters, Marilyn; Chan, Christina Y.; Vessey, S. J. R.; Kaplan, Karen M.; Kuter, Barbara J.

doi:10.1097/00006454-200206000-00014

Cited by 56 publications

(18 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As circulating antibody titers are known to vary over time based on the immunological state of the individual (Toptygina et al, 2005), the maternal antibody profile observed at the time of the registration of her child into the CHARGE study may be slightly different than during gestation. However, it has been demonstrated that antibodies, such as those generated in response to vaccination, can persist for many years due to the maintenance and subsequent polyclonal reactivation of memory B cells (Shinefield et al, 2002). It is currently unknown whether or not successive children from those mothers with reactivity to fetal brain will have autism.…”

Section: Discussionmentioning

confidence: 99%

Autism: Maternally derived antibodies specific for fetal brain proteins

et al. 2007

View full text Add to dashboard Cite

Autism is a profound disorder of neurodevelopment with poorly understood biological origins. A potential role for maternal autoantibodies in the etiology of some cases of autism has been proposed in previous studies To investigate this hypothesis, maternal plasma antibodies against human fetal and adult brain proteins were analyzed by western blot in 61 mothers of children with autistic disorder and 102 controls matched for maternal age and birth year (62 mothers of typically developing children (TD) and 40 mothers of children with non-ASD developmental delays (DD)). We observed reactivity to two protein bands at approximately 73kDa and 37kDa in plasma from 7 of 61 (11.5%) mothers of children with autism (AU) against fetal but not adult brain, which was not noted in either control group (TD; 0/62 p=0.0061 and DD; 0/40 p=0.0401). Further, the presence of reactivity to these two bands correlated with a diagnosis of behavioral regression in the child when compared to the TD (p=0.0019) and DD (0.0089) groups. Individual reactivity to the 37kDa band was observed significantly more often in the AU population compared with TD (p=0.0086) and DD (p=0.002) mothers, yielding a 5.69-fold odds ratio (95% confidence interval 2.09 -15.51) associated with this band. The presence of these antibodies in the plasma of some mothers of children with autism, as well as the differential findings between mothers of children with early onset and regressive autism may suggest an association between the transfer of IgG autoantibodies during early neurodevelopment and the risk of developing of autism in some children.

show abstract

Section: Discussionmentioning

confidence: 99%

Autism: Maternally derived antibodies specific for fetal brain proteins

et al. 2007

View full text Add to dashboard Cite

show abstract

“…GMTs were slightly but significantly lower in the group with concomitant MMR and varicella vaccine administration: 13.2 in the co-administered groups vs. 17.9 in the group given the vaccines six weeks apart (p<0.05) (Table 10). (67) …”

Section: Mmr and Varicella Vaccine Administrationmentioning

confidence: 99%

Literature Review on One-Dose and Two-Dose Varicella Vaccination

Campbell¹,

Ismail²,

Tan³

2010

Canada Communicable Disease Report

View full text Add to dashboard Cite

“…[1][2][3][4][5][9][10][11][12][13][14][15][16][17][18][19][20][21] There is no interference in immunoresponse to the varicella vaccine when it is administered simultaneously with other vaccines recommended for children; however, when the varicella vaccine is administered less than 1 month after the measles, mumps and rubella vaccine (MMR), reduced seroconversion rates are observed in response to the varicella virus. [1][2][3][9][10][11][12][13][14][15][16][17][18][19][20][21] Adverse events…”

Section: Immunogenicitymentioning

confidence: 99%

“…[13][14][15] The principal factors associated with primary and secondary vaccination failure are listed in Table 3. [9][10][11][12][13][14][15][16][17][18][19][20][21][22] The probability of a vaccinated individual suffering secondary vaccination failure is inversely proportional to the antibody titers 6 weeks after vaccination, [13][14][15] but almost all of those children who had secondary vaccination failure exhibited low severity varicella episodes, with few cutaneous lesions, the majority papules. [9][10][11][12][13][14][15][16][17][18][19][20][21][22] It is rare for vaccinated children to present vesicles; since the number of vesicles is directly related to transmission of the disease, circulation of VZV is reduced in communities with high levels of vaccination coverage.…”

Section: Immunogenicitymentioning

confidence: 99%

Vacinas contra varicela e vacina quádrupla viral

Bricks¹,

Sato²,

Oselka³

2006

J. Pediatr. (Rio J.)

View full text Add to dashboard Cite

Objectives: To present an up-to-date review of studies investigating the efficacy, adverse events and vaccination regimens of the varicella vaccine and the new presentation combined with the vaccine for measles, mumps and rubella.Sources of data: Bibliographic review of the MEDLINE and LILACS databases covering the period 1999 to 2006. Summary of the findings:The varicella vaccine protects 70 to 90% of immunized children against any form of varicella zoster infection, but the efficacy against severe forms is higher (95 to 98%). This is a well-tolerated vaccine that causes few reactions. Since the vaccine was licensed, there have been three confirmed cases of transmission of the vaccine virus by domestic contacts to previously healthy people, who went on to develop mild disease. Despite evidence that the protection offered by this vaccine can wane over a number of years, it is not yet possible to state that a second dose is warranted, bearing in mind exposure to wild virus. After universal vaccination the chances of natural stimulation should drop and it is very probable that booster doses will become necessary. A measles, mumps, rubella, and varicella vaccine has recently been licensed that combines vaccines for measles, mumps, rubella and varicella in a single product with high rates of seroconversion. Conclusions:The Brazilian Society of Pediatrics recommends the varicella vaccine for children from 1 year on. We hope that the measles, mumps, rubella, and varicella vaccine will soon be available in Brazil, since combined vaccines facilitate wider vaccination coverage.J Pediatr (Rio J). 2006;82(3 Suppl):S101-8: Varicella, adverse events, efficacy, vaccination schedule, measles, mumps, rubella, and varicella vaccine.

show abstract

Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children

Cited by 56 publications

References 16 publications

Autism: Maternally derived antibodies specific for fetal brain proteins

Autism: Maternally derived antibodies specific for fetal brain proteins

Literature Review on One-Dose and Two-Dose Varicella Vaccination

Vacinas contra varicela e vacina quádrupla viral

Contact Info

Product

Resources

About